Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature
  • Ali Al Sbihi
    DMC Sinai-Grace Hospital, Detroit, MI, USA
  • Nouraldeen Manasrah
    DMC Sinai-Grace Hospital, Detroit, MI, USA
  • Dahlia Sano
    Karmanos Cancer Centre/Wayne State University, Detroit, MI, USA

Keywords

COVID-19, multiple myeloma, lenalidomide

Abstract

We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.

VIEW THE ENTIRE ARTICLE

Views: 546
HTML downloads: 124
PDF downloads: 339


Published: 2022-03-09
Issue: 2022: Vol 9 No 3 (view)


How to cite:
1.
Al Sbihi A, Manasrah N, Sano D. Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature. EJCRIM 2022;9 doi:10.12890/2022_003216.

Most read articles by the same author(s)